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Abstract
Background: Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent
pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a
previous analysis assumed 87%.
Methods: This updated figure was applied to a previously published 10-year Markov model while holding all other
inputs constant.
Results: Our model estimated that the catch-up program as currently implemented is estimated to prevent an
additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine
PCV13 vaccination with no catch-up program.
Conclusions: Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series,
vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional
uptake of catch-up vaccination in the catch-up eligible cohort.
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Background
The 13-valent pneumococcal conjugate vaccine (PCV13)
has been available in the US for routine vaccination of
infants since March 2010. PCV13 provides protection
against Streptococcus pneumoniae serotypes 1, 3, 4, 5,
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. In February
2010, the Centers for Disease Control and Prevention
Advisory Committee on Immunization Practices (ACIP)
recommended routine vaccination of all children aged
2–59 months with PCV13, including administration of
PCV13 to all children not previously vaccinated with 7-
valent pneumococcal conjugate vaccine (PCV7), thereby
completing the vaccination series with PCV13 for all
children incompletely vaccinated with PCV7, and ad-
ministration of PCV13 as a fifth dose of conjugate
vaccine (a catch-up dose) for all children aged 14–
59 months who had been previously fully vaccinated
with PCV7 [1,2]. In addition, the ACIP advised that a
single dose of PCV13 may be administered for children
aged 6–18 years who have not received PCV13 previ-
ously but are at increased risk for invasive pneumococcal
disease (IPD), including pneumococcal meningitis or
bacteremia, regardless of whether they have previously
received PCV7 or 23-valent pneumococcal polysacchar-
ide vaccine [1,2].
A recently published model predicted that a PCV13
catch-up program would significantly reduce cases of
pneumococcal disease, reduce vaccine-preventable deaths,
and increase quality-adjusted life-years within the US
population [3]. The analysis indicated that medical cost-
offsets would likely be sufficient to cover the cost of the
catch-up dose for children aged ≤59 months, making the
catch-up program cost-saving under the condition that
the catch-up program accelerated establishment of indir-
ect (herd) effects by ≥6 months compared with no catch-
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ease Control and Prevention and a health advisory from
California highlight the importance of providing a catch-
up dose to eligible children [4,5]. With lower penetration
of the catch-up program, it is possible that the acceler-
ation of indirect effect would be <1 year. This short com-
munication presents the estimated impact of the catch-up
program with and without indirect effect acceleration,
using 15 months of administrative claims data to estimate
the catch-up program’s total uptake within the catch-up
eligible population.
Methods
The previous analysis assumed that 87% of eligible chil-
dren would receive a catch-up dose during the first year
of the PCV13 vaccination program [3], equivalent to the
percentage of eligible children expected to complete the
primary pneumococcal conjugate vaccination series [6].
For the present analysis, the original model was adapted
to include the estimate of actual uptake of PCV13 catch-
up [3]. To maintain consistency with the previous ana-
lysis all other model inputs remained as originally
reported [3]. Briefly, the decision-analytic model is a
Markov (state-transition) model with the starting point
being the choice of vaccination strategy [3]. The 10-year
model considers the entire US population, and allows
for inclusion of indirect effects. Within each annual
cycle, persons are subject to pneumococcal disease, in-
cluding IPD, all-cause pneumonia (PNE; hospitalized or
non-hospitalized), and all-cause acute otitis media
(AOM). During each cycle, persons may survive, die
from pneumococcal disease, or die from other causes.
Two methods were used to estimate the number of
catch-up vaccinations administered to children aged 15–
59 months during the observation period of April 2010
to June 2011; age 15–59 months was selected during the
model design phase before the ACIP provided its recom-
mendation of 14–59 months. With the first method,
catch-up vaccinations in both private and public markets
were estimated from the growth in shipments of PCV13
net of customer inventory changes versus historical ship-
ments made in support of the primary PCV7 series.
Product wastage was not considered in the model. From
this evidence, approximately 24% (3.8 million children)
of the age 15–59 month cohort were estimated to have
received a catch-up vaccination dose during the 15-
month observation period [unpublished data].
A second method was used to verify the private mar-
ket component results of the first method: private mar-
ket only catch-up vaccinations were estimated from
growth in SDI insurance claims (SDI claims only capture
the private market) for children aged 15–59 months dur-
ing the observation period versus the control period,
comprising the average claims in each month over the
prior 2 years (i.e. April 2008 through March 2010) [un-
published data]. Insurance claims for office visits within
the catch-up eligible cohort were stable over the control
period, thus providing a good baseline for comparison.
Claims data from SDI (private market only), also pre-
dicted an increase in office visits for vaccination of
catch-up eligible children during the observation period
of 24% [unpublished data].
In order to project the total uptake of catch-up over
the eligible period ending in December 2013, a separate
model was developed. Using observed increases of vac-
cination in children aged 14–59 months, age-specific
estimates of catch-up participation were obtained via a
financial forecasting model. Briefly, the catch-up eligible
population at PCV13 launch was based on census birth
estimates and National Health Interview Survey-
reported 4-dose compliance for PCV7. As time pro-
gressed in the model, children were removed from the
target population when they became age-ineligible or
were vaccinated with a catch-up dose. Age-relevant ‘well’
visit rates and catch-up vaccination rates were extrapo-
lated to estimate the future catch-up uptake of the
remaining eligible population. We assumed that as the
catch-up eligible cohort ages over time, their probability
of receiving a catch-up dose diminishes due to an in-
verse relationship between age and both vaccination
rates and recommended well-visit compliance. The
model utilized age-specific SDI claims data applied to
the catch-up eligible population [unpublished data]. This
model projected final uptake of catch-up among eligible
children (aged 15–59 months in March of 2010) to be
39% (6.4 million children).
We estimated cases of IPD, PNE and AOM, and
deaths in children aged ≤59 months over a 10-year time
horizon assuming different scenarios of uptake levels of
the catch-up program. Additionally, we calculated cases
of disease and deaths avoided due to catch-up at the
present level and those which could be further elimi-
nated with additional uptake of catch-up to 4-dose com-
pliance levels (87%).
The previous analysis assumed that implementation of
the catch-up program would accelerate accumulation of
indirect effects [3], such that full indirect effects would
be realized at 6 years as opposed to the 7 years observed
with the introduction of PCV7 vaccination [M.M.
Moore: unpublished data]. As we estimated that the
lower levels of catch-up vaccination may be inconsistent
with the strong acceleration of herd effect assumed in
the previous analysis [3], we examined the impact of
modifying the assumption of 1-year acceleration through
sensitivity analyses. We conducted analyses assuming
both 1-year and no acceleration of indirect effects in
children aged ≤59 months with the catch-up program,
and reported the impact of these assumptions.
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In the base case, the catch-up program as currently
implemented is estimated to prevent an additional 1.7
million cases of disease over 10 years in children aged
≤59 months compared with routine PCV13 vaccination
with no catch-up program (Table 1). Additional uptake
of the catch-up program to 4-dose compliance levels
would prevent an additional 0.7 million cases of disease
over 10 years compared with current catch-up levels.
In sensitivity analyses, when assuming no indirect-effect
acceleration (i.e. 7 years until the accumulation of full in-
direct effects), the current catch-up program is estimated
to prevent an additional 0.5 million cases of disease over
10 years in children aged ≤59 months compared with rou-
tine vaccination with PCV13 and no catch-up program
(Table 2). Additional uptake of the catch-up program to 4-
dose compliance levels is estimated to prevent an add-
itional 0.7 million cases of disease over 10 years compared
with current catch-up levels.
Discussion
Our analysis predicts a decline in IPD, PNE, and AOM
in children aged ≤59 months with the PCV13 catch-up
program. This catch-up program is predicted to have
better uptake than the previous PCV7 catch-up program
following the introduction of PCV7 [7]. Although a 39%
catch-up uptake is less than 87% completion of the 4-
dose primary PCV13 series, the program has reached
several million children. According to our analysis
catch-up has prevented substantial morbidity and mor-
tality due to pneumococcal disease; however, vaccine-
preventable cases of pneumococcal disease and related
deaths could be decreased further with additional uptake
of ACIP catch-up recommendations [2].
Our findings are consistent with the previous analysis
which examined disease reduction across all ages [3].
The catch-up program’s estimated cost-effectiveness is
unchanged by the percentage of children receiving
catch-up; therefore, the cost-effectiveness results, al-
though not discussed in the paper, are also consistent
with the previous analysis in that the program remains
cost-saving if indirect effects are accelerated by
≥6 months [3].
Under any scenario of catch-up coverage, infants con-
tinue to receive high levels of primary series coverage;
therefore, we assume that indirect effects caused by
PCV13 will be similar to the experience following PCV7.
The previous analysis assumed that the indirect effects
due to PCV13 would go through a 7-year ramp-up
period and that the increased population coverage of the
PCV13 catch-up program would accelerate this ramp-up
such that the full indirect effects would occur 1 year fas-
ter [3]. It is possible that with lower coverage of children
aged 15–59 months this acceleration could be muted.
This assumption has implications on the reduction of
disease in all non-vaccinated cohorts in the early years
of PCV13. If catch up is insufficient to accelerate the in-
direct effect, there is still an increase in the number of
cases of pneumococcal disease prevented as cases are
reduced in those children who do receive the catch up
dose. Most notably, if acceleration of indirect effects
occurs with 87% participation, but not with 39% partici-
pation, the model estimates an additional 2,263 IPD
cases, 115,807 PNE cases, 1.7 million AOM cases, and
95 deaths would occur over 10 years in children aged
≤59 months.
We have understated the benefits of increasing catch-
up coverage by excluding individuals aged ≥5 years from
the analysis because these individuals benefit from indir-
ect effects. There are additional limitations to this ana-
lysis. The model used to estimate the overall uptake of
the catch-up program relies on several assumptions.
Firstly, the observation period used to project office vis-
its for vaccination is relatively short as PCV13 has been
available since March 2010. Secondly, the increase in
office visits in the catch-up eligible cohort could be due
to other factors that are not yet fully understood in the
administrative claims data. Finally, as with any database
analysis, we rely on the generalizability of the sample
population to the overall US population. Of course, the









Cases prevented due to
catch-up (39%)
Additional cases potentially
prevented with increased catch-up
a
IPD 50,762 22,261 20,148 18,822 2,113 1,327
Hospitalized Pneumonia 1,203,733 940,580 916,018 900,426 24,562 15,592
Non-hospitalized
Pneumonia
14,828,732 14,037,214 13,958,633 13,905,915 78,581 52,718
AOM 161,033,859 144,731,659 143,125,025 142,466,963 1,606,634 658,062
Deaths 4,389 3,141 3,051 3,020 90 31
AOM: acute otitis media; IPD: invasive pneumococcal disease; PCV7: 7-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine.
aFrom 39% to 87%.
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to this analysis [3]. However, the claims analysis was re-
markably consistent with the secondary PCV13 inven-
tory analysis; therefore, we believe that the 39% estimate
is a reasonable estimate of the final uptake of catch-up.
Conclusion
According to our analysis, catch-up has prevented sub-
stantial morbidity and mortality due to pneumococcal dis-
ease; however, vaccine-preventable cases of pneumococcal
disease and related deaths could be decreased further with
additional uptake of ACIP catch-up recommendations [2].
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Table 2 Ten-years disease/mortality, children ≤59 months, multiple PCV13 catch-up scenarios, assuming no















IPD 22,261 21,048 19,637 1,176 1,448
Hospitalized Pneumonia 940,580 927,831 912,141 12,749 15,690
Non-hospitalized Pneumonia 14,037,214 13,994,317 13,941,520 42,897 52,797
AOM 144,731,659 144,194,812 143,534,078 536,847 660,735
Deaths 3,141 3,116 3,084 26 32
AOM: acute otitis media; IPD: invasive pneumococcal disease; PCV13: 13-valent pneumococcal conjugate vaccine.
aFrom 39% to 87%.
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